Blog Archives

Castle Biosciences’ DecisionDx-Melanoma Test Shown to be a Significant Predictor of Distant Metastasis in Elderly Patients with Melanoma

Friendswood, TX–March 20, 2017 Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that studies evaluating the prognostic performance and clinical impact of the DecisionDx®-Melanoma gene expression profile (GEP) test, including a cohort of elderly patients and four independent studies, were presented during the 70th Society of Surgical Oncology Annual Cancer Symposium (SSO) held in Seattle, WA from March 15-18. “We know that there is a decline in the rate of more »

Posted in News & Events

Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016

Results confirm accuracy of DecisionDx-Melanoma to identify recurrence risk  A second independent, prospective study confirms test accuracy Chicago, IL—June 6, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test, DecisionDx®-Melanoma, in 334 new melanoma patients. The data confirmed the positive results from two previously published multicenter clinical validation studies demonstrating the test’s ability to more »

Posted in News & Events

Independent Study Verifies the Performance of Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test for Predicting Risk of Metastasis

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced results of an independent study with its noninvasive gene expression profile test, verifying the accuracy and utility of the assay to identify risk of metastasis in patients diagnosed with Stage I or II cutaneous melanoma. Results were presented in an oral presentation session at the 48th Annual Meeting of the American College of Mohs Surgery in Orlando, FL. The study, titled more »

Posted in News & Events

Melanoma: Amid Caveats, New Test Shown to Improve Prediction of Risk of Metastasis and Survival

SAN FRANCISCO–A new gene expression profile (GEP) test more accurately predicts the risk of metastasis and survival in patients with cutaneous melanoma compared with the standard predictive method currently used to guide patient management, researchers reported here at the American Academy of Dermatology Annual Meeting. With more testing, they and other experts said, it may allow oncologists to know which patients need early treatment to prevent disease progression. “There is great variability in prognosis in more »

Posted in News & Events

Study Shows Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test Improves Identification of High Risk Disease in Tumors of Intermediate T2/T3 Thickness

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced updated study results with its noninvasive gene expression profile (GEP) test, demonstrating that the assay was able to accurately identify high risk disease in patients with tumors of intermediate thickness (T2/T3), independent of sentinel lymph node biopsy (SLNB) status and ulceration. The data are being presented today at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) during more »

Posted in News & Events

New Gene Expression Profile Test Used in Combination with Sentinel Lymph Node Biopsy Improves Prediction of Metastasis and Death in Patients with Head and Neck Melanoma

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile (GEP) test significantly improved the prognostic value of sentinel lymph node biopsy (SLNB)—a standard predictive method—in identifying patients with cutaneous melanomas of the head and neck at high risk of their cancer spreading. The data were presented last week at the Society of Surgical Oncology (SSO) Annual Cancer Symposium. The study,“Gene Expression more »

Posted in News & Events

Study Demonstrates New Noninvasive Gene Expression Profile Test Predicts Melanoma Risk More Accurately Than AJCC Online Predictor Tool

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, today announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile (GEP) test was significantly more accurate in predicting risk of metastasis and survival in patients with cutaneous melanoma than a standard predictive method currently used to guide patient management. The data were presented during the 73rd Annual Meeting of the American Academy of Dermatology (AAD). The study, titled “Melanoma Risk Prediction of more »

Posted in News & Events

GEP test for melanoma proves accurate in validation study

Recently released results of a clinical validation study suggest that a new gene expression profile (GEP) test is effective for cutaneous melanoma. The study concludes that DecisionDx-Melanoma, a GEP test from Castle Biosciences Inc., Friendswood, Texas, accurately predicts metastatic risk in Stage I or Stage II melanoma patients who have no sign of disease beyond the original tumor. The study finds that the test can predict independent of current diagnostic modalities, including American Joint Committee more »

Posted in News & Events

Gene expression profiling, SLNB improved prediction of metastasis risk in patients with melanoma

A gene expression profile test improved identification of the metastasis risk in patients with melanoma who underwent sentinel lymph node biopsy, according to recently published study results. “The outcomes for patients with cutaneous melanoma are highly variable and there are limitations to the conventional staging system for melanoma,” researcher Pedram Gerami, MD, told Healio.com/Dermatology. “For example, although the status of the sentinel lymph node biopsy [SLNB] is considered the strongest prognosticator, approximately two-thirds of cutaneous melanoma patients who ultimately die from their more »

Posted in News & Events

Study Shows Castle Biosciences’ Noninvasive Skin Melanoma Gene Test Improves Accuracy of Sentinel Lymph Node Biopsy in Predicting Metastasis

Castle Biosciences, Inc. today announced the publication of a clinical study showing that its gene expression profile (GEP) test for cutaneous (skin) melanoma improved the prognostic accuracy of sentinel lymph node biopsy (SLNB) in identifying patients at high risk of their cancer spreading. The GEP test was able to identify as high risk a significant number of patients whose sentinel lymph node biopsy results did not indicate any increased risk, but who subsequently developed metastatic more »

Posted in News & Events
Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation